1. Home
  2. PASG vs AEON Comparison

PASG vs AEON Comparison

Compare PASG & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PASG

Passage Bio Inc.

HOLD

Current Price

$5.20

Market Cap

26.0M

Sector

Health Care

ML Signal

HOLD

Logo AEON Biopharma Inc.

AEON

AEON Biopharma Inc.

HOLD

Current Price

$0.78

Market Cap

25.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PASG
AEON
Founded
2017
N/A
Country
United States
United States
Employees
27
8
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.0M
25.8M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
PASG
AEON
Price
$5.20
$0.78
Analyst Decision
Buy
Strong Buy
Analyst Count
7
1
Target Price
$14.00
$7.20
AVG Volume (30 Days)
64.6K
67.6K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$0.53
52 Week High
$20.00
$1.45

Technical Indicators

Market Signals
Indicator
PASG
AEON
Relative Strength Index (RSI) 42.65 35.97
Support Level $3.94 $0.70
Resistance Level $5.74 $0.82
Average True Range (ATR) 0.38 0.06
MACD 0.18 -0.01
Stochastic Oscillator 69.53 22.00

Price Performance

Historical Comparison
PASG
AEON

About PASG Passage Bio Inc.

Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.

About AEON AEON Biopharma Inc.

AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.

Share on Social Networks: